These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11472235)

  • 61. Structure-function relationships of hammerhead ribozymes: from understanding to applications.
    Sigurdsson ST; Eckstein F
    Trends Biotechnol; 1995 Aug; 13(8):286-9. PubMed ID: 7662303
    [TBL] [Abstract][Full Text] [Related]  

  • 62. In vitro and in vivo cleavage of HIV-1 RNA by new SOFA-HDV ribozymes and their potential to inhibit viral replication.
    Lainé S; Scarborough RJ; Lévesque D; Didierlaurent L; Soye KJ; Mougel M; Perreault JP; Gatignol A
    RNA Biol; 2011; 8(2):343-53. PubMed ID: 21422817
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Colocalizing ribozymes with substrate RNAs to increase their efficacy as gene inhibitors.
    Sullenger BA
    Appl Biochem Biotechnol; 1995; 54(1-3):57-61. PubMed ID: 7486985
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The hammerhead ribozyme.
    Eckstein F; Bramlage B
    Biopolymers; 1999; 52(3):147-54. PubMed ID: 11169382
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of activities between hammerhead ribozymes and DNA enzymes targeted to L6 BCR-ABL chimeric (b2a2) mRNA.
    Warashina M; Kuwabara T; Taira K
    Nucleic Acids Symp Ser; 1997; (37):213-4. PubMed ID: 9586075
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Can hammerhead ribozymes be efficient tools to inactivate gene function?
    Bertrand E; Pictet R; Grange T
    Nucleic Acids Res; 1994 Feb; 22(3):293-300. PubMed ID: 7510389
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Trans-splicing ribozymes for targeted gene delivery.
    Köhler U; Ayre BG; Goodman HM; Haseloff J
    J Mol Biol; 1999 Feb; 285(5):1935-50. PubMed ID: 9925776
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Ribozyme-targeted destruction of RNA associated with autosomal-dominant retinitis pigmentosa.
    Drenser KA; Timmers AM; Hauswirth WW; Lewin AS
    Invest Ophthalmol Vis Sci; 1998 Apr; 39(5):681-9. PubMed ID: 9538873
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Transcripts containing a small anti-HIV hammerhead ribozyme that are active in the cell cytoplasm but inactive in vitro as free RNAs.
    Domi A; Beaud G; Favre A
    Biochimie; 1996; 78(7):654-62. PubMed ID: 8955908
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Repurposing Antiviral Drugs for Orthogonal RNA-Catalyzed Labeling of RNA.
    Ghaem Maghami M; Dey S; Lenz AK; Höbartner C
    Angew Chem Int Ed Engl; 2020 Jun; 59(24):9335-9339. PubMed ID: 32162405
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of the antiviral efficacy of ribozymes and antisense RNA directed against bovine leukemia virus rex/tax.
    Cantor GH; Stone DM; McElwain TF; Palmer GH
    Antisense Nucleic Acid Drug Dev; 1996; 6(4):301-4. PubMed ID: 9012866
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Ribozymes: structure, characteristics and use as potential antiviral agents.
    Bartolomé J; Madejón A; Carreño V
    J Hepatol; 1995; 22(1 Suppl):57-64. PubMed ID: 7602079
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA.
    Kuwabara T; Warashina M; Tanabe T; Tani K; Asano S; Taira K
    Nucleic Acids Res; 1997 Aug; 25(15):3074-81. PubMed ID: 9224607
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Design and optimization of sequence-specific hairpin ribozymes.
    Romero-López C; Barroso-delJesus A; Puerta-Fernández E; Berzal-Herranz A
    Methods Mol Biol; 2004; 252():327-38. PubMed ID: 15017061
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Assessing adenoviral hammerhead ribozyme and small hairpin RNA cassettes in neurons: inhibition of endogenous caspase-3 activity and protection from apoptotic cell death.
    Bantounas I; Glover CP; Kelly S; Iseki S; Phylactou LA; Uney JB
    J Neurosci Res; 2005 Mar; 79(5):661-9. PubMed ID: 15657876
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Preparations of hammerhead ribozymes for investigations of their cleavable sequences.
    Tateoka H; Kawahara I; Hasegawa S; Haruta K; Kondo Y; Kojima C; Tanaka Y
    Nucleic Acids Symp Ser (Oxf); 2009; (53):277-8. PubMed ID: 19749368
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Inhibition of c-Ha-ras gene expression by hammerhead ribozymes containing a stable C(UUCG)G hairpin loop.
    Koizumi M; Kamiya H; Ohtsuka E
    Biol Pharm Bull; 1993 Sep; 16(9):879-83. PubMed ID: 8268855
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Inhibition of human immunodeficiency virus type 1 replication by nuclear chimeric anti-HIV ribozymes in a human T lymphoblastoid cell line.
    Michienzi A; Conti L; Varano B; Prislei S; Gessani S; Bozzoni I
    Hum Gene Ther; 1998 Mar; 9(5):621-8. PubMed ID: 9551610
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Inhibition of viral replication by ribozyme: mutational analysis of the site and mechanism of antiviral activity.
    Zhang Z; Burke JM
    J Virol; 2005 Mar; 79(6):3728-36. PubMed ID: 15731266
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Repression of hepatitis B virus X gene expression by hammerhead ribozymes.
    Kim YK; Junn E; Park I; Lee Y; Kang C; Ahn JK
    Biochem Biophys Res Commun; 1999 Apr; 257(3):759-65. PubMed ID: 10208856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.